RecruitingEarly Phase 1NCT07707531
A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
Sponsor
Huashan Hospital
Enrollment
10 participants
Start Date
Jun 1, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This study is to evaluate the safety, biodistribution, radiation dosimetry and tumor uptake of the \[68Ga\]/ \[131I\]-IR199 in patients with Claudin 18.2 positive gastric cancer and pancreatic cancer.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called [68Ga]/ [131I]-IR199 for people with gastric cancer and pancreatic cancer. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUG[68Ga]/ [131I]-IR199
\[68Ga\]/ \[131I\]-IR199, single dose
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07707531
Related Trials
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT0706665720 locations
IDOV-Immune for Advanced Solid Tumors
NCT069106575 locations
WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment
NCT062913241 location
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
NCT0727741316 locations
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT0697411015 locations